[go: up one dir, main page]

NO20073239L - TNF-antagonister - Google Patents

TNF-antagonister

Info

Publication number
NO20073239L
NO20073239L NO20073239A NO20073239A NO20073239L NO 20073239 L NO20073239 L NO 20073239L NO 20073239 A NO20073239 A NO 20073239A NO 20073239 A NO20073239 A NO 20073239A NO 20073239 L NO20073239 L NO 20073239L
Authority
NO
Norway
Prior art keywords
tnf
polypeptides
treatment
binding
tnf antagonists
Prior art date
Application number
NO20073239A
Other languages
English (en)
Inventor
Thor Las Holtet
Mikkel Holmen Andersen
Mette Munch
Helle Krogh Ottow
Josephus Dirk Nieland
Original Assignee
Anaphore Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaphore Inc filed Critical Anaphore Inc
Publication of NO20073239L publication Critical patent/NO20073239L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Sammendrag TNF-bindende polypeptider basert på humane tetranektin C-type lectinliknende domener (TTLD) med forbedret bindingsegenskaper og forbedret effektivitet. Polypeptidene omfatter et TNF-bindende domene med aminosyresekvensen KRWSRYF (SEQ ID NO: l). Det frembringes også fremgangsmåte for å fremstille polypetiden ifølge oppfinnelsen. Polypeptidene kan anvendes for fremstilling av farmasøytiske sammensetninger, og for behandling av et individ som har en patologi mediert TNF, slik som behandling av reumatoid artritt.
NO20073239A 2004-11-22 2007-06-22 TNF-antagonister NO20073239L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62934304P 2004-11-22 2004-11-22
DKPA200401813 2004-11-22
PCT/DK2005/000742 WO2006053568A1 (en) 2004-11-22 2005-11-21 Tnf antagonists

Publications (1)

Publication Number Publication Date
NO20073239L true NO20073239L (no) 2007-08-17

Family

ID=35840156

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073239A NO20073239L (no) 2004-11-22 2007-06-22 TNF-antagonister

Country Status (10)

Country Link
US (1) US7820622B2 (no)
EP (1) EP1824878A1 (no)
JP (1) JP2008520214A (no)
KR (1) KR20070095296A (no)
AU (1) AU2005306168A1 (no)
BR (1) BRPI0518042A (no)
CA (1) CA2587948A1 (no)
NO (1) NO20073239L (no)
NZ (1) NZ555353A (no)
WO (1) WO2006053568A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080032343A1 (en) 2005-12-22 2008-02-07 Genentech, Inc. Recombinant Production of Heparin Binding Proteins
KR101520105B1 (ko) * 2006-07-14 2015-05-21 제넨테크, 인크. 재조합 단백질의 리폴딩
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
EP2072527A1 (en) 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
CN102099373A (zh) 2008-05-22 2011-06-15 百时美施贵宝公司 基于纤连蛋白的多价支架结构域蛋白
CA2739663A1 (en) * 2008-10-10 2010-05-15 Anaphore, Inc. Polypeptides that bind trail-r1 and trail-r2
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
CN107056921B (zh) * 2017-03-23 2020-06-19 桂林八加一药业股份有限公司 一种选择性tnfr1拮抗肽sn10及其在炎症性肠病中的应用
US11124558B2 (en) * 2017-06-02 2021-09-21 The Feinstein Institutes For Medical Research Use of tetranectin and peptide agonists to treat inflammatory diseases
EP3773913A1 (en) 2018-04-11 2021-02-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9409768D0 (en) 1994-05-16 1994-07-06 Medical Res Council Trimerising polypeptides
DE69827507T2 (de) 1997-06-11 2006-03-09 Borean Pharma A/S Trimerisierendes modul
WO2002048189A2 (en) 2000-12-13 2002-06-20 Borean Pharma A/S Combinatorial libraries of proteins having the scaffold structure of c-type lectin-like domains
AU2003225416A1 (en) 2002-06-25 2004-01-06 Medical Patents Limited Injection syringe having a retractable injection needle
EP2311867A1 (en) 2002-10-29 2011-04-20 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines

Also Published As

Publication number Publication date
JP2008520214A (ja) 2008-06-19
CA2587948A1 (en) 2006-05-26
US20090155843A1 (en) 2009-06-18
KR20070095296A (ko) 2007-09-28
WO2006053568A1 (en) 2006-05-26
EP1824878A1 (en) 2007-08-29
AU2005306168A1 (en) 2006-05-26
US7820622B2 (en) 2010-10-26
NZ555353A (en) 2009-12-24
BRPI0518042A (pt) 2008-10-28

Similar Documents

Publication Publication Date Title
NO20073239L (no) TNF-antagonister
JP7440581B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
RU2381233C2 (ru) Агонисты рецептора меланокортина
CN104507961B (zh) 抗炎性肽及包含其的组合物
WO2004101611A3 (en) Peptides that bind to the erythropoietin receptor
WO2006052723A3 (en) G protein coupled receptor agonists and antagonists and methods of use
ATE417595T1 (de) Keratin-bindende polypeptide
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
NO20070496L (no) Kimere proteiner og anvendelser derav.
WO2010135491A3 (en) Fibroblast growth factor mutants having improved functional half-life and methods of their use
WO2004069876A3 (en) Trimeric polypeptide construct to induce an enduring t cell response
SI3191511T1 (en) Improved TNF binders
MXPA03003902A (es) Polipeptidos de proquineticina, composiciones relacionadas y metodos.
NZ599114A (en) Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
HUP0402496A2 (hu) Módosított polipeptidek
MX2012001278A (es) Anticuerpos de dominio simple anti-receptor tgf-beta tipo ii.
CN118354781A (zh) 白介素-23受体的肽抑制剂
Garcia‐Redondo et al. Vascular effects of egg white‐derived peptides in resistance arteries from rats. Structure–activity relationships
WO2003002604A3 (en) G protein coupled receptors and dna sequences thereof
ES2987275T3 (es) Péptido antagonista de la actividad de la interleucina-15
CN116199744B (zh) 一种结合fgfr2受体的多肽及其用途
JPWO2021229076A5 (no)
WO2006097432A3 (de) Keratin-biktdende desmoplakinpolypeptidsequenzen
EA200801077A1 (ru) Антагонисты взаимодействия pf4 и rantes
JP2022536797A (ja) 炎症性状態を処置するための方法および組成物

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO

FC2A Withdrawal, rejection or dismissal of laid open patent application